



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/778,961	02/08/2001	Chunhua Yan	CL001113	5818

25748 7590 01/26/2005

CELERA GENOMICS CORP.
ATTN: WAYNE MONTGOMERY, VICE PRES, INTEL PROPERTY
45 WEST GUDE DRIVE
C2-4#20
ROCKVILLE, MD 20850

EXAMINER

SAIDHA, TEKCHAND

ART UNIT	PAPER NUMBER
----------	--------------

1652

DATE MAILED: 01/26/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 09/778,961	Applicant(s) YAN ET AL.	
	Examiner Tekchand Saidha	Art Unit 1652	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 24 August 2004.
- 2a) ☐ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-23 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☐ Claim(s) _____ is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☒ Claim(s) 1-23 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

Election/Restrictions

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-2 & 20-21, drawn to human Phospholipase of SEQ ID NO: 2, classified in class 435, subclass 198.
- II. Claim 3, drawn to antibody that selectively binds to the human Phospholipase of SEQ ID NO: 2, classified in class 530, subclass 387.1.
- III. Claims 4-6, 8-11 & 22-23, drawn to Nucleic acid(s) (SEQ ID NO: 1, coding; SEQ ID NO: 3, genomic) encoding human Phospholipase of SEQ ID NO: 2, vector, host cell and method of making the Phospholipase, classified in class 435, subclass 198.
- IV. Claim 7, drawn to transgenic non-human animal transformed with the nucleic acid encoding human Phospholipase of SEQ ID NO: 2, classified in class 800, subclass 8.
- V. Claim 12, drawn to a method of detecting human Phospholipase & fragments thereof, classified in class 435, subclass 4.
- VI. Claim 13, drawn to a method of detecting the presence of nucleic acid encoding SEQ ID NO: 2 and fragments thereof, classified in class 435, subclass 6.
- VII. Claims 14-15, drawn to a method of identifying modulator of human Phospholipase of SEQ ID NO: 2, classified in class 435, subclass 69.2.
- VIII. Claims 16-17, drawn to method of identifying an agent that binds to any of the peptides of claim 2, including human Phospholipase of SEQ ID NO: 2 or fragments thereof, classified in class 435, subclass 18.

Art Unit: 1652

- IX. Claim 18, drawn to a method of treating a disease or condition mediated by human Phospholipase of SEQ ID NO: 2, classified in class 424, subclass 94.6.
- X. Claim 19, drawn to a method of identifying modulator of the expression of a peptide or human Phospholipase of SEQ ID NO: 2, classified in class 536, subclass 24.5.

2. The inventions are distinct, each from the other because of the following reasons:

The DNA encoding the phospholipase of Group III and phospholipase of Group I are chemically and biologically distinct molecules. The enzyme and DNA have fundamentally different molecular structure, each with its own set of functionality. Enzyme, for example is biologically active, whereas DNA encoding the enzyme, is not. Additionally, the DNA constitutes the genetic material and is composed of the genes, and has other functions besides encoding the enzyme. Since the phospholipase and the DNA are biologically and chemically distinct, the manner of using the DNA may not necessarily involve the enzyme.

The proteins of Invention I are related to the antibodies of Invention II by virtue of being the cognate antigen, necessary for the production of antibodies. Although the protein and antibody are related due to the necessary steric complementarity of the two, they are distinct Inventions because the protein can be used in another and materially different process from the use for the production of the antibody, such as in a pharmaceutical composition in its own right, or to assay or purify the natural ligand of the protein (if the protein is itself a receptor), or in assays for the identification of agonists or antagonists of the receptor protein.

The nucleic acid of Invention III and the antibody of Invention II are related by virtue of the protein that is encoded by the nucleic acid and necessary for the production of the antibody. However, the nucleic acid itself is not necessary for antibody production and both are wholly different

compounds having different compositions and functions. Therefore, these Inventions are distinct.

The protein of Invention I and the transgenic animal of Invention IV are unrelated and therefore patentably distinct. Similarly the antibody of Invention II and the transgenic animal of Invention IV are unrelated and therefore patentably distinct, have differing structure do not require one for the practice of the other.

Inventions III and IV are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (M.P.E.P. § 806.05(h)). In the instant case the phospholipase encoding nucleic acid molecules, as claimed in Group III, can be used in a materially different process other than in the making of transgenic non-human animal as claimed in Group IV, such as use of the nucleic acids in a method to produce recombinant phospholipase.

The methods of Inventions V, VI, VII, VIII, IX and X are related in that each method requires the use of Phospholipase, or the DNA encoding the phospholipase. However, the steps and end points of the methods are wholly different and therefore Inventions V, VI, VII, VIII, IX and X are patentably distinct.

3. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

The examiner has required restriction between product and process claims.

Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. **Process claims**

Art Unit: 1652

that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai*, *In re Brouwer* and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder.

Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

5. A telephone call was not made to request an oral election to the above restriction requirement. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Art Unit: 1652

6. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

7. **Sequence Rules compliance is requested prior to making an election to the above restriction requirement.**

The specification contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR § 1.821(a) and (a)(2). However, the specification fails to comply with one or more of the requirements of 37 CFR § 1.821 through 1.825 as follows: In order to comply Applicants are required to submit (1) A computer readable form (CRF) of the sequence listing; (2) A paper copy of the sequence listing as part of the specification; and (3) a statement that the CRF and the paper copy are identical. Please refer to the Compliance requirements of 37 CFR 1.821 through 1.825 is in the MPEP.

Appropriate corrections for compliance are required.

New Sequence Rules

Since the effective filing date after July 1, 1998, Applicants should follow the New Rule Format and submit a new Sequence Listing (both in electronic and paper format). Compliance according to the requirements of 37 CFR 1.821 through 1.825 is required.


8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Tekchand Saidha whose telephone number is (571) 272 0940. The examiner can normally be reached on 8.30 am - 5.00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapu Achutamurthy can be reached on (571)

Art Unit: 1652

272 0928. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



Tekchand Saidha
Primary Examiner, Art Unit 1652
Recombinant Enzymes, E03A61 Remsen Bld.
400 Dulany Street, Alexandria, VA
Telephone : (571) 272-0940

January 21, 2005